https://www.selleckchem.com/pr....oducts/lomeguatrib.h
N stage increased in 51 patients (17.7%), 32 (11.1%) to N2 disease. Mean survival in those upstaged was 43.5 (39.9-47.1) months versus 53.4 (50.0-56.8) months in patients not upstaged (p=0.025). Mean recurrence-free survival in those upstaged was 39.1 (35.2-43. months versus 47.7 (43.9-51.4) months in patients not upstaged (p=0.117). Upstaging was independently associated with inferior survival (HR 1.674, p=0.006) and inferior recurrence-free survival (HR 1.423, p=0.038). A significant number of patients are upstaged between diagn
Like
Comment
Share
